March is Colorectal Cancer Awareness Month, a time to highlight the importance of early detection and screening. In this context, we turn our attention to the Phase 3 BLUE-C Study, which played a pivotal role in the FDA's approval of Cologuard Plus. Approved on October 4, 2024, Cologuard Plus is an advanced, non-invasive colorectal cancer screening test intended for adults aged 45 years and older at average risk for colorectal cancer. The test incorporates additional biomarkers and refined laboratory processes, designed to enhance both sensitivity and specificity in detecting colorectal cancer and precancerous lesions.

This study is recognized as one of the most comprehensive and large-scale clinical trials conducted to assess the performance of a colorectal cancer screening test. Over 20,000 participants, representing the diverse racial and ethnic demographics of the United States, were enrolled, all aged 40 and older. The goal was to develop a test that would improve the sensitivity for colorectal cancer detection while also addressing the issue of false-positive results.

The findings from the BLUE-C study demonstrated that Cologuard Plus met all of the primary study endpoints, showing significant improvements across key performance metrics. Notably, the test exhibited a 30% reduction in the false-positive rate compared to the DeeP-C trial, the pivotal FDA study for the original Cologuard test. Furthermore, Cologuard Plus achieved a 94% sensitivity for detecting colorectal cancer, with a specificity of 91% for non-advanced findings and 93% for no findings. The test's specificity was even higher in younger age groups, reaching 96% among individuals aged 45-54 years. These improvements in specificity help minimize the number of unnecessary follow-up colonoscopies, reducing the burden of false-positive results.

Here is a brief overview of the study:

Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"

Study Details | Source

  • Sponsor: Exact Sciences Corporation
  • The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.
  • Interventions:
    • Diagnostic Test: mt-sDNA 2.0 screening test
    • Diagnostic Test: FIT test
    • Procedure: Colonoscopy
  • Primary Outcome Measures
    • Sensitivity for CRC with the mt-sDNA 2.0 test
      • Time Frame: Through study completion, an average of 180 days
    • Specificity with the mt-sDNA 2.0 test
      • Through study completion, an average of 180 days

Data from the Centers for Disease Control and Prevention (CDC) indicate that the widespread use of Cologuard has contributed significantly to the increase in colorectal cancer screening rates, rising from 63% in 2015 to 72% in 2021 among U.S. adults aged 50 to 75.

In summary, the approval of Cologuard Plus represents a meaningful step forward in colorectal cancer screening, offering improved accuracy and reducing unnecessary procedures, all while enhancing accessibility for at-risk populations.

We highly value your input and welcome any thoughts or insights you may have on this topic. Additionally, we encourage you to sign up for alerts to stay informed on the latest published guidelines and articles. Thank you for your continued support and engagement in advancing medical research and treatment options.

Copyright © 2025 Guideline Central, all rights reserved.